<?xml version="1.0" encoding="UTF-8"?>
<p id="p0130">Other antivirals that are currently being tested include umifenovir, oseltamivir, darunavir/cobicistat combination (
 <xref rid="f0095" ref-type="fig">Fig. 19</xref> ). Umifenovir is used for the treatment of influenza in Russia and China. Umifenovir exhibits its action by preventing the fusion of the virus with the cell membrane blocking its entry into the host cell 
 <xref rid="b0570" ref-type="bibr">[114]</xref>. Oseltamivir, also used for the treatment of influenza viruses, acts as a neuraminidase inhibitor, preventing the release of new virus particles 
 <xref rid="b0575" ref-type="bibr">[115]</xref>. Darunavir is a protease inhibitor approved for the treatment of HIV, and cobicistat prevents the catabolism of darunavir 
 <xref rid="b0580" ref-type="bibr">[116]</xref>. Clinical trials are underway to evaluate the efficacy of these drugs for treating COVID-19.
</p>
